Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-136960

Published: 2020

Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141552

Published: 2020

Journal Articles

Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT

Blood (2020) 136 (Supplement 1): 45–47.

https://doi.org/10.1182/blood-2020-142397

Published: 2020

Journal Articles

Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

John F. Seymour, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Matthew S. Davids, MD, Anthony Mato, MD, Jeff P Sharman, MD, Aimee Cyr, Cynthia Bartkus, German Pena, MD, Michelle Boyer, Simon Sharmokh, MPH, PharmD, Tanya S Rosenberg, MD, William G. Wierda, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134938

Published: 2020

Journal Articles

Immune System Deregulation Predicts Outcome in Diffuse Large B Cell Lymphoma (DLBCL)

Edward Truelove, MBBS, BSc, MRCP, FRCPath, Joseph G Taylor, MBBS, BSc, Andrew James Clear, BSc, Mariarita Calaminici, Professor John G. Gribben, MD DSc

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-143104

Published: 2020

Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Blood (2020) 136 (Supplement 1): 37–39.

https://doi.org/10.1182/blood-2020-134783

Published: 2020

Journal Articles

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

James Aries, Sarah Charrot, Jennifer Ball, Matthew Mee, Symeon Theocharidis, Sofie Van Gassen, Sameena Iqbal, John G. Gribben, MD DSc, Jeff Davies, MBBS, PhD

Blood (2019) 134 (Supplement_1): 595.

https://doi.org/10.1182/blood-2019-124875

Published: 2019

Journal Articles

Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment

Joseph G Taylor, MBBS, BSc, Andrew James Clear, BSc, Edward Truelove, MBBS, BSc, MRCP, FRCPath, Mariarita Calaminici, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 658.

https://doi.org/10.1182/blood-2019-125247

Published: 2019

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 324.

https://doi.org/10.1182/blood-2019-128795

Published: 2019

Journal Articles

CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS

Robin Sanderson, MRCP,FRCPath, Arantxa Romero-Toledo, MSc, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 249.

https://doi.org/10.1182/blood-2019-125647

Published: 2019

Journal Articles

The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets

Edward Truelove, MBBS, BSc, MRCP, FRCPath, Frances Seymour, MRCP, BSc, MBBS, Joseph G Taylor, MBBS, BSc, Mariarita Calaminici, Andrew James Clear, BSc, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 5240.

https://doi.org/10.1182/blood-2019-130712

Published: 2019

Journal Articles

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Blood (2019) 134 (Supplement_1): 4575.

https://doi.org/10.1182/blood-2019-127166

Published: 2019

Journal Articles

Treatment with Acalibrutinib, Ibrutinib and CD19 CAR T Cells Restore the Number of Granulocytic Myeloid Derived Supressor Cells in CLL-Bearing Mice

Arantxa Romero-Toledo, MSc, Robin Sanderson, MRCP,FRCPath, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 3032.

https://doi.org/10.1182/blood-2019-126697

Published: 2019

Journal Articles

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Laurie H Sehn, MD, Marek Trněný, MD, Kamal Bouabdallah, MD, Gregory Dueck, MD, John G. Gribben, MD DSc, P.J. Lugtenburg, MD PhD, Gilles A. Salles, MD PhD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Wenxin Liu, PhD, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2822.

https://doi.org/10.1182/blood-2019-123422

Published: 2019

Journal Articles

CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34 + Cells

Emily A Saunderson, PhDBSc, Kevin Rouault-Pierre, PhDBSc, John G. Gribben, MD DSc, Gabriella Ficz, PhDBSc

Blood (2019) 134 (Supplement_1): 2517.

https://doi.org/10.1182/blood-2019-130267

Published: 2019

Journal Articles

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Blood (2019) 134 (Supplement_1): 2769.

https://doi.org/10.1182/blood-2019-124352

Published: 2019

Journal Articles

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

Jennifer Edelmann, MD PhD, Arran Dokal, MSc, PhD, Karlheinz Holzmann, Dr. rer. nat., David James Britton, BSc, PhD, Emma Vilventhraraja, MSc, PhD, Ryan Jack Smith, PhD, Mark S Cragg, Prof, Andrejs Braun, PhD, Hartmut Döhner, MD, Pedro Cutillas, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 1579.

https://doi.org/10.1182/blood-2019-128704

Published: 2019

Journal Articles

TNFRSF14 aberrations in Follicular Lymphoma B Cells Result in Increased Alloresponses in Vitro and in Vivo

Eleni Kotsiou, PhD, Jessica Okosun, MD, Andrew James Clear, BSc, Sameena Iqbal, BSc, Jude Fitzgibbon, PhD, John G. Gribben, MD DSc, Jeff K. Davies, MD PhD

Blood (2014) 124 (21): 2426.

https://doi.org/10.1182/blood.V124.21.2426.2426

Published: 2014

Journal Articles

Overexpression of BCL-2 Does Not Inhibit Autophagy in Human Follicular and Diffuse Large B-Cell Lymphomas

Aine McCarthy, PhD, Andrew James Clear, BSc, Jacek Marzec, Rita Coutinho, MD, Robert D. Petty, PhD, Janet Matthews, Andrew Wilson, Sameena Iqbal, Maria Calaminici, MD PhD, John G. Gribben, MD DSc, Li Jia, PhD MD

Blood (2014) 124 (21): 3007.

https://doi.org/10.1182/blood.V124.21.3007.3007

Published: 2014

NARROW

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT

Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

Immune System Deregulation Predicts Outcome in Diffuse Large B Cell Lymphoma (DLBCL)

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS

The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Treatment with Acalibrutinib, Ibrutinib and CD19 CAR T Cells Restore the Number of Granulocytic Myeloid Derived Supressor Cells in CLL-Bearing Mice

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34 + Cells

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

TNFRSF14 aberrations in Follicular Lymphoma B Cells Result in Increased Alloresponses in Vitro and in Vivo

Overexpression of BCL-2 Does Not Inhibit Autophagy in Human Follicular and Diffuse Large B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only